Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BASEL, MAY 7, 2026  NOVARTIS, A LEADING GLOBAL INNOVATIVE MEDICINES COMPANY, TODAY BROKE GROUND ON ITS NEW 46,000 SQ. FT RADIOLIGAND THERAPY (RLT) MANUFACTURING SITE IN DENTON, TEXAS, THE LATEST MILESTONE IN ITS BROADER $23BILLION INVESTMENT IN US MANUFACTURING AND RESEARCH. THE START OF CONSTRUCTION ON THE COMPANY'S FIRST TEXASBASED MANUFACTURING FACILITY BRINGS US RLT PRODUCTION CLOSER TO PATIENTS ACROSS THE SOUTHERN US, BECOMING THE FIFTH RLT SITE NATIONWIDE. RADIOLIGAND THERAPY IS TRANSFORMING HOW WE TREAT CANCER, AND EXPANDED MANUFACTURING IS ESSENTIAL TO DELIVERING THESE THERAPIES AT SCALE, SAID VAS NARASIMHAN, CEO OF NOVARTIS. BREAKING GROUND IN DENTON FURTHER STRENGTHENS OUR US SUPPLY CHAIN AND HELPS ENSURE PATIENTS CAN RECEIVE THESE HIGHLY PERSONALIZED TREATMENTS WHEN AND WHERE THEY NEED THEM. THIS EXPANSION REINFORCES NOVARTIS' LEADERSHIP AS THE FIRST COMPANY TO DELIVER RLT AT SCALE, BUILDING THE NETWORK CAPACITY NEEDED AS THESE THERAPIES EXTEND INTO EARLIER STAGES OF TREATMENT AND A BROADER RANGE OF CANCERS. ANNOUNCED EARLIER THIS YEAR, THE SITE IS EXPECTED TO BECOME OPERATIONAL IN 2028 AND CREATE NEW US-BASED NOVARTIS JOBS IN BIOENGINEERING, ADVANCED MANUFACTURING, QUALITY, AND OPERATIONS, SUPPORTING ECONOMIC GROWTH IN DENTON AND SURROUNDING COMMUNITIES. US UNDER SECRETARY OF COMMERCE FOR INDUSTRY AND SECURITY JEFFREY KESSLER, SWISS AMBASSADOR TO THE US RALF HECKNER, TEXAS STATE SENATOR BRENT HAGENBUCH, TEXAS STATE REPRESENTATIVE ANDY HOPPER, AND DENTON MAYOR GERARD HUDSPETH JOINED NOVARTIS LEADERSHIP, EMPLOYEES, AND COMMUNITY PARTNERS TO CELEBRATE THE START OF CONSTRUCTION. I'M PLEASED TO WELCOME NOVARTIS TO DENTON AS THEIR NEWEST MANUFACTURING LOCATION FOR THEIR CANCER THERAPIES, SAID TEXAS STATE SENATOR BRENT HAGENBUCH. THEIR DECISION ESTABLISHES A STRONG PARTNERSHIP AND REFLECTS THE UNIQUE OPPORTUNITY DENTON PROVIDES TO A WELL-EDUCATED WORKFORCE, AND THE UNIQUE ACCESS THE NEW PLANT LOCATION WILL PROVIDE TO THE VIBRANT NORTH TEXAS ECONOMY AND RAPIDLY 

NOVARTIS BREAKS GROUND ON DENTON, TEXAS RADIOLIGAND THERAPY SITE; CONSTRUCTION NOW UNDERWAY ACROSS ALL NEW US FACILITIES

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR FIRST QUARTER NET SALES DECLINED -5% (CC 1 , -1% USD), AS GROWTH DRIVERS WERE MORE THAN OFFSET BY US GENERIC EROSION CONTINUED STRONG PERFORMANCE FROM PRIORITY BRANDS INCLUDING KISQALI (+55% CC), PLUVICTO (+70% CC), KESIMPTA (+26% CC), SCEMBLIX (+79% CC) AND LEQVIO (+69% CC) CORE OPERATING INCOME 1 DOWN -14% (CC, -12% USD), DUE TO LOWER NET SALES AND HIGHER R&D INVESTMENT CORE OPERATING INCOME MARGIN1 WAS 37.3% OPERATING INCOME DECLINED -11% (CC, -9% USD); NET INCOME DOWN -13% (CC, -13% USD) CORE EPS 1 DECLINED -15% (CC, -13% USD) TO USD 1.99 FREE CASH FLOW 1 WAS USD 3.3 BILLION, BROADLY IN LINE WITH THE PRIOR-YEAR QUARTER Q1 SELECTED INNOVATION MILESTONES: REMIBRUTINIB POSITIVE CHMP OPINION FOR CSU, POSITIVE PHASE III READOUT IN CINDU AND PHASE II DATA IN FOOD ALLERGY IANALUMAB FDA BREAKTHROUGH THERAPY DESIGNATION AND PRIORITY REVIEW IN SJD COSENTYX FDA APPROVAL FOR PEDIATRIC HS PATIENTS, REGULATORY SUBMISSIONS FOR PMR FABHALTA POSITIVE PHASE III EGFR RESULTS IN IGAN, FDA PRIORITY REVIEW FOR TRADITIONAL APPROVAL COMPLETED ACQUISITION OF AVIDITY, ADDING THREE LATE-STAGE MEDICINES ADDRESSING NEUROMUSCULAR DISEASE FULL YEAR 2026 GUIDANCE 2 REAFFIRMED NET SALES EXPECTED TO GROW LOW SINGLE-DIGIT AND CORE OPERATING INCOME EXPECTED TO DECLINE LOW SINGLE-DIGIT BASEL, APRIL 28, 2026  COMMENTING ON Q1 2026 RESULTS, VAS NARASIMHAN, CEO OF NOVARTIS, SAID: NOVARTIS DELIVERED A STRONG START TO 2026 ACROSS OUR PRIORITY BRANDS AND LAUNCHES, WHILE US GENERIC EROSION WEIGHED ON RESULTS IN Q1 AS EXPECTED.

NOVARTIS DELIVERED STRONG GROWTH IN PRIORITY BRANDS AND LAUNCHES IN Q1; FY 2026 GUIDANCE REAFFIRMED

BASEL, APRIL 27, 2026  NOVARTIS ANNOUNCED TODAY THAT THE EUROPEAN COMMISSION (EC) APPROVED RHAPSIDO (REMIBRUTINIB) FOR CHRONIC SPONTANEOUS URTICARIA (CSU) IN ADULT PATIENTS WITH INADEQUATE RESPONSE TO H1-ANTIHISTAMINE TREATMENT. RHAPSIDO IS THE FIRST ORAL TARGETED TREATMENT APPROVED FOR CSU, OFFERING A UNIQUE APPROACH TO CSU TREATMENT IN A PILL TAKEN TWICE DAILY WITHOUT ANY LAB MONITORING REQUIRED1.

NOVARTIS RHAPSIDO RECEIVESEUROPEAN COMMISSIONAPPROVAL ASFIRSTORAL TARGETED TREATMENT FOR CHRONIC SPONTANEOUS URTICARIA

BASEL, APRIL 24, 2026 NOVARTIS TODAY ANNOUNCED THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF THE EUROPEAN MEDICINES AGENCY (EMA) HAS ADOPTED APOSITIVE OPINION RECOMMENDING MARKETING AUTHORIZATION FOR ITVISMA (INTRATHECAL ONASEMNOGENE ABEPARVOVEC). THE OPINION SUPPORTS ITS USE FOR THE TREATMENT OF CHILDREN TWO YEARS AND OLDER, TEENS, AND ADULTS LIVING WITH 5Q SPINAL MUSCULAR ATROPHY (SMA) WITH A BI-ALLELIC MUTATION IN THE SURVIVAL MOTOR NEURON 1 (SMN1) GENE.

NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR ITVISMA FOR SPINAL MUSCULAR ATROPHY (SMA)

BASEL, APRIL 24, 2026  NOVARTIS TODAY ANNOUNCED THAT THE WORLD HEALTH ORGANIZATION (WHO) HAS PREQUALIFIED COARTEM (ARTEMETHER-LUMEFANTRINE) BABY, THE FIRST AND ONLY ANTIMALARIAL DEVELOPED SPECIFICALLY FOR NEWBORNS AND YOUNG INFANTS WEIGHING FROM 2 TO 5 KILOGRAMS. THE DECISION IS A KEY STEP TOWARDS ENABLING WIDESPREAD ACCESS THROUGH PUBLIC SECTOR PROCUREMENT. COARTEM BABY IS ALSO KNOWN AS RIAMET BABY IN SOME COUNTRIES AND WAS DEVELOPED IN COLLABORATION WITH MEDICINES FOR MALARIA VENTURE (MMV).

NOVARTIS MALARIA TREATMENT COARTEM BABY RECEIVES WHO PREQUALIFICATION, PAVING WAY FOR GREATER ACCESS FOR NEWBORNS AND YOUNG INFANTS

BOSTON--(BUSINESS WIRE)--INSTEM ANNOUNCES THE APPOINTMENT OF SZCZEPAN BARAN, VMD, MS, AS CHIEF SCIENTIFIC OFFICER TO LEAD INSTEM'S SCIENTIFIC AND AI STRATEGY.

INSTEM TAPS EX-NOVARTIS HEAD OF EMERGING TECHNOLOGIES TO PUT SCIENCE BEHIND PRACTICAL AI AND NAMS

EAST HANOVER, APRIL 9, 2026  NOVARTIS TODAY ANNOUNCED THE EXPANSION OF ITS PROGRAMS TO FIND AND TREAT PATIENTS WITH HEART DISEASE AND CANCER IN HARD-TO-REACH COMMUNITIES AROUND THE WORLD. THIS COMES AS PUBLIC HEALTH EFFORTS AGAINST CHRONIC DISEASES SLOW OR REVERSE IN MANY COUNTRIES.1 THREE DISTINCT NOVARTIS COMMUNITY HEALTH APPROACHES FOCUSED ON CLOSING GAPS IN CARE FOR LOW-INCOME, RURAL AND OTHER COMMUNITIES WILL NEARLY TRIPLE FROM 11 TO MORE THAN 30 COUNTRIES BY 2030, INCLUDING:

NOVARTIS ANNOUNCES EXPANSION OF COMMUNITY HEALTH PROGRAMS TO CLOSE GAPS IN HEART DISEASE AND CANCER CARE, TARGETING MORE THAN 30 COUNTRIES BY 2030

BASEL, MARCH 29, 2026  NOVARTIS TODAY ANNOUNCED FINAL TWO-YEAR RESULTS FROM THE PHASE III APPLAUSEIGAN STUDY OF FABHALTA (IPTACOPAN) IN IGA NEPHROPATHY (IGAN). FABHALTA DEMONSTRATED A STATISTICALLY SIGNIFICANT, CLINICALLY MEANINGFUL IMPROVEMENT IN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) SLOPE, A KEY MARKER OF KIDNEY FUNCTION, COMPARED WITH PLACEBO1. FABHALTA CONSISTENTLY OUTPERFORMED PLACEBO ACROSS KEY KIDNEY OUTCOMES OVER TWO YEARS, DEMONSTRATING A SLOWING OF DISEASE PROGRESSION AND THE POTENTIAL TO PRESERVE KIDNEY FUNCTION IN IGAN1. THE RESULTS WERE PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE AND SIMULTANEOUSLY PRESENTED AS LATEBREAKING DATA AT THE 2026 WORLD CONGRESS OF NEPHROLOGY (WCN).

NOVARTIS IGAN DATA IN NEW ENGLAND JOURNAL OF MEDICINE SHOW FABHALTA SLOWED KIDNEY FUNCTION DECLINE BY 49.3%

 ACQUISITION BRINGS TOGETHER EXCELLERGY'S DIFFERENTIATED TRIFUNCTIONAL ALLERGIC EFFECTOR CELL RESPONSE INHIBITORS (ECRIS) AND THE DEVELOPMENT EXPERTISE OF NOVARTIS, WITH A TOTAL POTENTIAL TRANSACTION VALUE OF UP TO $2 BILLION   EXL-111 IS A POTENTIALLY FIRST-IN-CLASS ALLERGIC TRIFUNCTIONAL ECRI TARGETING THE IGE AXIS AND IS CURRENTLY IN PHASE 1 DEVELOPMENT  PALO ALTO, CALIF., MARCH 27, 2026 (GLOBE NEWSWIRE) -- EXCELLERGY, A BIOTECHNOLOGY COMPANY DEVELOPING A NOVEL CLASS OF ALLERGY THERAPEUTICS, TODAY ANNOUNCED IT WILL BE ACQUIRED BY NOVARTIS IN A TRANSACTION WITH A TOTAL POTENTIAL VALUE OF UP TO $2 BILLION IN UPFRONT AND MILESTONE PAYMENTS.

EXCELLERGY TO BE ACQUIRED BY NOVARTIS FOR UP TO USD 2 BILLION TO ADVANCE POTENTIALLY FIRST-IN-CLASS TRIFUNCTIONAL EFFECTOR CELL RESPONSE INHIBITORS

-PROPOSED ACQUISITION STRENGTHENS NOVARTIS IMMUNOLOGY STRATEGY IN FOOD ALLERGY AND OTHER IGE-DRIVEN DISEASES   - LEAD ASSET EXL-111 BUILDS ON PROVEN IGE BIOLOGY WITH A DIFFERENTIATED MECHANISM DESIGNED TO DISSOCIATE RECEPTOR-BOUND IGE AND DRIVE FASTER, DEEPER PATHWAY SUPPRESSION   - EXL-111 WOULD COMPLEMENT EXISTING NOVARTIS PORTFOLIO IN ALLERGY WITH POTENTIAL TO IMPROVE BOTH SYMPTOM CONTROL AND CONVENIENCE  BASEL, MARCH 27, 2026  NOVARTIS TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT TO ACQUIRE EXCELLERGY, INC., A PRIVATE BIOTECH COMPANY DEVELOPING NEXT-GENERATION ANTI-IGE THERAPIES FOR IGE-DRIVEN DISEASES. THE PROPOSED ACQUISITION ADDS EXL-111, A HALF-LIFE EXTENDED, HIGH-AFFINITY ANTI-IGE ANTIBODY IN PHASE 1. THE ACQUISITION BUILDS ON DEEP NOVARTIS EXPERTISE IN IGE BIOLOGY AND A LONG-STANDING PRESENCE IN ALLERGIC DISEASE. EXL-111 IS DESIGNED AS A NEXT-GENERATION EXTENSION OF VALIDATED BIOLOGY ESTABLISHED BY ANTI-IGE THERAPY, WITH THE POTENTIAL TO COMPLEMENT THE NOVARTIS EXISTING ALLERGY PORTFOLIO ACROSS A RANGE OF ALLERGIC CONDITIONS AND PATIENT SETTINGS.EXCELLERGY ADDS A DIFFERENTIATED NEXT-GENERATION ANTI-IGE PROGRAM THAT BUILDS ON BIOLOGY NOVARTIS KNOWS WELL, SUPPORTED BY PRECLINICAL EVIDENCE AND EARLY CLINICAL PHARMACOKINETIC DATA, SAID FIONA MARSHALL, PRESIDENT OF BIOMEDICAL RESEARCH AT NOVARTIS. EXL-111 IS DESIGNED TO GO BEYOND CONVENTIONAL ANTI-IGE THERAPY, WITH THE POTENTIAL TO DELIVER FASTER AND DEEPER SUPPRESSION OF IGE SIGNALING AS WELL AS IMPROVED SYMPTOM CONTROL. THIS PROPOSED ACQUISITION STRENGTHENS OUR ALLERGY PORTFOLIO AND REFLECTS OUR STRATEGY OF ADVANCING INNOVATIVE BOLD SCIENCE TO BRING MEANINGFUL ADDITIONAL BENEFITS TO PATIENTS.IGE IS A CENTRAL DRIVER OF MULTIPLE ALLERGIC DISEASES. UNLIKE CONVENTIONAL ANTI-IGE APPROACHES, EXL-111 IS DESIGNED TO DISSOCIATE RECEPTOR-BOUND IGE WITH THE POTENTIAL TO DRIVE FASTER AND DEEPER FC EPSILON RI ALPHA (FCRI) DOWNREGULATION. PRECLINICAL STUDIES AND EARLY HUMAN PHARMACOKINETIC DATA FROM ONGOING PHASE 

NOVARTIS AGREES TO ACQUIRE EXCELLERGY, INC., BUILDING ON ALLERGY LEADERSHIP WITH NEXT-GENERATION ANTI-IGE INNOVATION

BASEL, MARCH 23, 2026  NOVARTIS WILL PRESENT DATA FROM MORE THAN 20 ABSTRACTS FROM ITS GROWING IMMUNOLOGY PORTFOLIO AT THIS YEAR'S AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING.

NOVARTIS PRESENTS NEW DATA ON EARLY SYMPTOM RELIEF AND LONG-TERM CONTROL IN COMPLEX SKIN DISEASES AT AAD 2026

WILMINGTON, DEL.--(BUSINESS WIRE)--SYNNOVATION THERAPEUTICS, LLC (SYNNOVATION), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY WITH A DIVERSE PIPELINE OF NOVEL SMALL-MOLECULE TARGETED THERAPIES IN ONCOLOGY AND IMMUNOLOGY TODAY ANNOUNCED A DEFINITIVE AGREEMENT FOR NOVARTIS TO ACQUIRE PIKAVATION THERAPEUTICS, INC. (PIKAVATION) AND ITS PORTFOLIO OF PI3K INHIBITOR PROGRAMS, INCLUDING SNV4818. PIKAVATION IS A WHOLLY-OWNED SUBSIDIARY OF SYNNOVATION. SNV4818 IS A POTENTIALLY BEST-IN-CLASS PAN-MUTANT SELE.

NOVARTIS TO ACQUIRE SYNNOVATION THERAPEUTICS' PAN-MUTANT SELECTIVE PI3K INHIBITOR PROGRAM

BASEL, MARCH 20, 2026  NOVARTIS TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT WITH SYNNOVATION THERAPEUTICS, LLC TO ACQUIRE SNV4818, A PAN-MUTANTSELECTIVE PI3K INHIBITOR, EXPLORING A NEXT-GENERATION APPROACH FOR THE TREATMENT OF PATIENTS WITH HR+/HER2- BREAST CANCER AND POTENTIALLY OTHER SOLID TUMOR INDICATIONS.

NOVARTIS AGREES TO ACQUIRE A PAN-MUTANT-SELECTIVE PI3K INHIBITOR, STRENGTHENING ITS BREAST CANCER PIPELINE

BASEL, MARCH 13, 2026  NOVARTIS ANNOUNCED TODAY THAT COSENTYX(SECUKINUMAB) RECEIVED US FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL FOR TREATINGPEDIATRICPATIENTS12 YEARS AND OLDER WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA (HS),MAKING IT THE ONLY IL-17A INHIBITOR FOR THIS POPULATION1.THE APPROVAL OF A DISTINCT BIOLOGIC OPTION FORPEDIATRIC PATIENTSLIVINGWITH HSALLOWS TREATMENT TO BE TAILORED TO THE INDIVIDUAL AND ESTABLISHES COSENTYXASA MEANINGFUL ADDITION TO THE TREATMENT LANDSCAPE1-13.

Novartis AG

NVS

Price

Financial Reports

No items found.

Press Releases

Novartis AG

NVS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NVS